Long-term outcomes and immune profiling in children with multisystem inflammatory syndrome (MIS-C)
Keywords:
MIS-C, follow-up observation, echocardiography, electrocardiogram, immunophenotyping, CD95, CD279Abstract
Background and aim: Existing follow-up data after MIS-C is limited. Purpose of the study: to investigate the long-term consequences in children who have undergone MIS-C.
Methods: The retrospective study included 93 children. The identified changes were divided into the following periods: occurred within first 6 months, 1 year, 2 years, and more than 2 years after MIS-C. Besides, 31 children underwent prospective immunophenotyping of peripheral blood and the determination of cytokines during the acute period of the disease and after discharge.
Results: Outpatient monitoring events included pneumonia (9.6%), somatic disorder syndrome (11.8%), visual impairment (7.5%), joint damage (6.6%), weight changes (2.2%), and MIS-C recurrence (2.2%). A study of the cardiovascular system showed a statistically significant decrease in the frequency of the right and left heart dilatation, left ventricular dysfunction, pericarditis, pulmonary arterial hypertension, coronaritis, mitral regurgitation. But at the same time an increase in pulmonary and tricuspid valve regurgitation and arrhythmias compared with the acute period was detected. Most of the changes took place within first year of observation.
Immune profiling showed reconstitution of CD3, CD4 T-lymphocytes, NK-cells, maintenance of a high relative value of CD8, reduction of CD19+ B-cells, expression of CD3-HLA-DR+, CD25, CD279, CD95.
Conclusions: After the history of MIS-C, children in the long-term follow-up had various somatic disorders and disease recurrence. Most patients (64.1%) showed subclinical signs of myocardial involvement within first year of observation. Low expression of CD95 may justify an certain role in the pathogenesis of the disease.
References
Noval Rivas M, Porritt RA, Cheng MH, Bahar I, Arditi M. Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis. Front Immunol. 2022 Jul 7;13:941009. doi: 10.3389/fimmu.2022.941009.
Das N, Hill R, Trivedi M, et al. Longitudinal Assessment of Cardiac Function Following Multisystem Inflammatory Syndrome in Children Associated with COVID-19. Pediatr Cardiol. 2023 Mar;44(3):607-617. doi: 10.1007/s00246-022-02972-3.
Sezer M, Çelikel E, Tekin ZE, et al. Multisystem inflammatory syndrome in children: clinical presentation, management, and short- and long-term outcomes. Clin Rheumatol. 2022 Dec;41(12):3807-3816. doi: 10.1007/s10067-022-06350-5.
Lin J, Harahsheh AS, Raghuveer G, et al. Emerging Insights Into the Pathophysiology of Multisystem Inflammatory Syndrome Associated With COVID-19 in Children. Can J Cardiol. 2023 Jan 7:S0828-282X(23)00004-1. doi: 10.1016/j.cjca.2023.01.002.
Rajamanickam A, Nathella PK, Venkataraman A, et al. Unique cellular immune signatures of multisystem inflammatory syndrome in children. PLoS Pathog. 2022 Nov 2;18(11):e1010915. doi: 10.1371/journal.ppat.1010915.
Carter MJ, Fish M, Jennings A, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. 2020 Nov;26(11):1701-1707. doi: 10.1038/s41591-020-1054-6.
Ricci-Vitiani L, Conticello C, Zeuner A, De Maria R. CD95/CD95L interactions and their role in autoimmunity. APOPTOSIS. 2000;5(5):419–24.
Jiang TT, Martinov T, Xin L, et al. Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4 T Cells to Protect against Autoimmunity. Cell Rep. 2016 Nov 8;17(7):1783-1794. doi: 10.1016/j.celrep.2016.10.042.
Patel JM. Multisystem Inflammatory Syndrome in Children (MIS-C). Curr Allergy Asthma Rep. 2022 May;22(5):53-60. doi: 10.1007/s11882-022-01031-4.
Tong T, Yao X, Lin Z, et al. Similarities and differences between MIS-C and KD: a systematic review and meta-analysis. Pediatr Rheumatol Online J. 2022 Dec 5;20(1):112. doi: 10.1186/s12969-022-00771-x.
Jaxybayeva I, Boranbayeva R, Abdrakhmanova S, et al. Comparative Analysis of Clinical and Laboratory Data in Children with Multisystem Inflammatory Syndrome Associated with SARS-CoV-2 in the Republic of Kazakhstan. Mediterr J Hematol Infect Dis. 2022 Sep 1;14(1):e2022064. doi: 10.4084/MJHID.2022.064.
Irfan O, Muttalib F, Tang K, Jiang L, Lassi ZS, Bhutta Z. Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. Arch Dis Child. 2021 Feb 16;106(5):440–8. doi: 10.1136/archdischild-2020-321385.
Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Heal. 2021 Jul;5(7):473–82. doi: 10.1016/S2352-4642(21)00138-3.
Pawar RS, Tarkasband VA, Patil RK, Naik AV. Second Episode of Multisystem Inflammatory Syndrome in Children: Relapse, Rebound, or Recurrence? Pediatr Infect Dis J. 2021 Nov 1;40(11):e452. doi: 10.1097/INF.0000000000003249.
Chakraborty A, Johnson JN, Spagnoli J, et al. Long-Term Cardiovascular Outcomes of Multisystem Inflammatory Syndrome in Children Associated with COVID-19 Using an Institution Based Algorithm. Pediatr Cardiol. 2023 Feb;44(2):367-380. doi: 10.1007/s00246-022-03020-w.
Capone CA, Misra N, Ganigara M, et al. Six Month Follow-up of Patients With Multi-System Inflammatory Syndrome in Children. Pediatrics. 2021 Oct;148(4):e2021050973. doi: 10.1542/peds.2021-050973.
Sperotto F, Friedman KG, Son MBF, VanderPluym CJ, Newburger JW, Dionne A. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. Eur J Pediatr. 2021 Feb;180(2):307-322. doi: 10.1007/s00431-020-03766-6.
Valverde I, Singh Y, Sanchez-de-Toledo J, Theocharis P, Chikermane A, Di Filippo S, et al. Acute Cardiovascular Manifestations in 286 Children With Multisystem Inflammatory Syndrome Associated With COVID-19 Infection in Europe. Circulation. 2021 Jan 5;143(1):21–32. doi: 10.1161/CIRCULATIONAHA.120.050065.
Jaxybayeva I, Boranbayeva R, Bulegenova M, Urazalieva N. Clinical and immunological features in children with multisystem inflammatory syndrome associated with SARS-CoV-2. Acta Biomed. 2023 Apr 24;94(2):e2023016. doi: 10.23750/abm.v94i2.13777.
Okarska‐Napierała M, Mańdziuk J, Feleszko W, et al. Recurrent assessment of lymphocyte subsets in 32 patients with multisystem inflammatory syndrome in children (MIS‐C). Pediatr Allergy Immunol. 2021 Nov 11;32(8):1857–65. doi: 10.1111/pai.13611.
Liu Y, Gao Y, Hao H, Hou T. CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. FEBS Open Bio. 2020 Jun;10(6):1162-1170. doi: 10.1002/2211-5463.12865.
Paulsen M, Janssen O. Pro- and anti-apoptotic CD95 signaling in T cells. Cell Commun Signal. 2011 Apr 8;9:7. doi: 10.1186/1478-811X-9-7.
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010 Jul;236:219-42. doi: 10.1111/j.1600-065X.2010.00923.x.
Paulsen M, Janssen O. Pro- and anti-apoptotic CD95 signaling in T cells. Cell Commun Signal. 2011 Apr 8;9:7. doi: 10.1186/1478-811X-9-7.
Koncz G, Hueber AO. The Fas/CD95 Receptor Regulates the Death of Autoreactive B Cells and the Selection of Antigen-Specific B Cells. Front Immunol. 2012 Jul 25;3:207. doi: 10.3389/fimmu.2012.00207.
Fife BT, Pauken KE. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci. 2011 Jan;1217:45-59. doi: 10.1111/j.1749-6632.2010.05919.x.
Bellesi S, Metafuni E, Hohaus S, et al. Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients. Br J Haematol. 2020 Oct;191(2):207-211. doi: 10.1111/bjh.17034.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Indira Jaxybayeva, Riza Boranbayeva, Minira Bulegenova, Nataliya Urazalieva, Valentin Gerein, Lyazat Manzhuova
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
